Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 12/20 | 0.49 |
| ▸ | CTSK | P43235 | 10/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1626495 | 0.83 | CTSS (0.54) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL3544394 | 0.83 | CTSS (0.54) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL5019146 | 0.83 | CTSS (0.54) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL5018896 | 0.82 | CTSS (0.55) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL15501136 | 0.82 | MEN1 (0.53) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL25715929 | 0.82 | CAPN1 (0.53) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL13170285 | 0.82 | CAPN1 (0.53) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL18975551 | 0.82 | CAPN1 (0.53) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL13055405 | 0.81 | SYK (0.54) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL2581187 | 0.80 | PPARA (0.48) | CTSSCTSKCTSLCTSBCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178490-B2 | Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010054102-A2 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCB1, SLC47A1 | CTSS 1281/4885CTSK 1390/4885CTSL 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.